WuXi Biologics (OTCPK:WXXWY) inks an agreement with Aravive (NASDAQ:ARAV) aimed at developing high-affinity bispecific antibodies for a target in cancer and fibrosis called CCN2.
Under the terms of the partnership, Aravive will
have access to the former’s WuXiBody platform and will be responsible
for preclinical and clinical development while WuXi will be responsible
for discovery, process development and manufacturing.
Financial terms remain confidential.
https://seekingalpha.com/news/3566839-wuxi-teams-up-aravive-to-develop-biologics-for-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.